1. Home
  2. FEMY vs ALLR Comparison

FEMY vs ALLR Comparison

Compare FEMY & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.47

Market Cap

23.2M

Sector

Health Care

ML Signal

HOLD

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.50

Market Cap

19.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEMY
ALLR
Founded
2004
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.2M
19.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
FEMY
ALLR
Price
$0.47
$1.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$5.50
$9.75
AVG Volume (30 Days)
363.1K
130.6K
Earning Date
05-08-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
44.71
N/A
EPS
N/A
N/A
Revenue
$2,293,313.00
$320,000.00
Revenue This Year
$105.16
N/A
Revenue Next Year
$200.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40.77
N/A
52 Week Low
$0.31
$0.77
52 Week High
$1.16
$2.35

Technical Indicators

Market Signals
Indicator
FEMY
ALLR
Relative Strength Index (RSI) 61.01 65.64
Support Level $0.33 $1.47
Resistance Level $0.58 $1.82
Average True Range (ATR) 0.03 0.09
MACD 0.01 0.00
Stochastic Oscillator 94.53 73.68

Price Performance

Historical Comparison
FEMY
ALLR

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.

Share on Social Networks: